

20 Nov 2008

Dear Consultee/Commentator

Health Technology Appraisal

NICE Technology Appraisal for adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after failure of a previous TNF- α inhibitor

Appeal panel decision

The Appeal Panel met on 29 September 2008 to consider the appeals lodged against the Final Appraisal Determination (FAD) for the above appraisal. The decision of the Panel has been received and is enclosed with this letter.

The Panel's decision will be posted on the web site on 24 November 2008. Until then, the contents of this letter and the decision remain confidential. In the event of an unauthorised disclosure of the decision, the Institute reserves the right to publish the decision immediately.

This appraisal is now ended. The Institute has written to the Department of Health to seek advice about whether a new formal referral is required. We will let you know the Departments response when we receive it.

If you have any queries regarding this appraisal, please contact the project manager, Jeremy Powel (Jeremy.powell@nice.org.uk).

Yours sincerely

Carole Longson
Director, Centre for Health Technology Evaluation